On Soriot’s List For AstraZeneca: Building A Decision-Making Culture

AstraZeneca investors will have to wait two more months to hear details of CEO Pascal Soriot’s plans for re-energizing the struggling big pharma. But the new chief did discuss several near-term objectives for the company and what he has pinpointed as being some of the operational problems, based on discussion with hundreds of employees, during a year-end financial call Jan. 31.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet